Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Hong Kong Orders GSK Pediatric Antibiotic Withdrawn From Market

This article was originally published in PharmAsia News

Executive Summary

Hong Kong health authorities ordered GlaxoSmithKline's Augmentin (amoxillin) pediatric antibiotic pulled from the market after hospitals found a plastics chemical in samples

Hong Kong health authorities ordered GlaxoSmithKline's Augmentin (amoxillin) pediatric antibiotic pulled from the market after hospitals found a plastics chemical in samples.

The drug, made by GSK in plants in France, was found to contain plasticizers at double the levels allowed by European regulators. Major Hong Kong public hospitals rely on Augmentin as the first treatment for fighting infections in children, but the Hong Kong Hospital Authority said it would substitute other drugs. (Click here for more)

"Antibiotic Is Recalled Over Chemical Find" - South China Morning Post (Hong Kong) (6/10/11

Table

View full table

Tags:
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC078175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By